Drug Guide

Generic Name

Itraconazole

Brand Names Sporanox, Onmel, Tolsura

Classification

Therapeutic: Antifungal

Pharmacological: Imidazole Antifungal

FDA Approved Indications

  • Treatment of fungal infections including histoplasmosis, blastomycosis, aspergillosis, onychomycosis, and other systemic fungal infections

Mechanism of Action

Itraconazole inhibits fungal cytochrome P450 14α-demethylase, decreasing ergosterol synthesis which impairs fungal cell membrane formation.

Dosage and Administration

Adult: Dosage varies based on infection; typically, 200 mg once or twice daily. For onychomycosis, typically 200 mg once daily for 12 weeks.

Pediatric: Use is limited; dosing based on weight and age. Consult specific guidelines.

Geriatric: Use with caution; monitor liver function. Dosage adjustments may be necessary.

Renal Impairment: Use with caution; no specific dosage adjustment recommended but monitor closely.

Hepatic Impairment: Use with caution; consider lower doses due to hepatic metabolism.

Pharmacokinetics

Absorption: Variable; enhanced with acidic gastric pH, take with food.

Distribution: Widely distributed, including skin, nails, lungs, and CSF.

Metabolism: Primarily hepatic via CYP3A4 enzyme.

Excretion: Excreted mainly in feces, some in urine.

Half Life: approximately 30-40 hours.

Contraindications

  • Hypersensitivity to itraconazole or other azole antifungals.
  • Concomitant use with certain medications like terfenadine, astemizole, cisapride (due to risk of QT prolongation).

Precautions

  • Liver disease, heart failure, or arrhythmias. Use cautiously in pregnancy and lactation. Monitor liver function and cardiac status.

Adverse Reactions - Common

  • Gastrointestinal upset (nausea, diarrhea) (Frequent)
  • Nausea, vomiting, abdominal pain (Common)

Adverse Reactions - Serious

  • Liver toxicity (hepatitis, liver failure) (Uncommon)
  • QT prolongation, arrhythmias (Rare)
  • Heart failure worsening (Rare)

Drug-Drug Interactions

  • Rifampin, certain statins, oral hypoglycemics, cyclosporine, certain benzodiazepines, QT prolonging drugs

Drug-Food Interactions

  • Gastric acid-suppressing agents may reduce absorption.

Drug-Herb Interactions

N/A

Nursing Implications

Assessment: Monitor liver function tests, renal function, and cardiac status. Assess for signs of systemic fungal infections.

Diagnoses:

  • Risk for hepatotoxicity
  • Risk for cardiac arrhythmias

Implementation: Administer with food to enhance absorption; monitor for adverse effects; educate patient on signs of liver toxicity and cardiac issues.

Evaluation: Evaluate clinical response, monitor laboratory tests regularly, ensure patient adherence.

Patient/Family Teaching

  • Take medication with food or after meals.
  • Report signs of liver problems (jaundice, dark urine, fatigue).
  • Avoid QT-prolonging drugs and herbal supplements without medical advice.
  • Do not stop medication abruptly.

Special Considerations

Black Box Warnings:

  • Heart failure risk, especially in patients with pre-existing heart disease.

Genetic Factors: CYP3A4 interactions can alter drug levels.

Lab Test Interference: May affect liver function tests.

Overdose Management

Signs/Symptoms: Nausea, vomiting, dizziness, abnormal ECG changes.

Treatment: Supportive care; activated charcoal if ingestion was recent; no specific antidote.

Storage and Handling

Storage: Store at room temperature, away from light and moisture.

Stability: Stable under recommended conditions for the duration of the shelf life.

This guide is for educational purposes only and is not intended for clinical use.